← Back to Search

Targeted Immunotherapy for Leukemia (ALLO-T-DART Trial)

Phase 1
Recruiting
Research Sponsored by New York Medical College
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
T-cell ALL in second or subsequent remission (≤ 5% blasts) or relapsed T-cell LLy with complete response after re-induction therapy
Performance status ≥ 60%
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

ALLO-T-DART Trial Summary

This trial will test if a targeted immunotherapy drug is safe for kids with T-cell leukemia/lymphoma after a bone marrow transplant. It will look at how the drug affects their recovery.

Who is the study for?
This trial is for children, adolescents, and young adults (0-39 years old) with high-risk T-cell acute lymphoblastic leukemia or lymphoma in remission or complete response after therapy. They must be planning a stem cell transplant, have good performance status, recovered from previous treatments' effects, meet organ function criteria, and not be pregnant or breastfeeding.Check my eligibility
What is being tested?
The trial tests the safety of daratumumab immunotherapy following total body irradiation and stem cell transplantation in patients with T-cell leukemia/lymphoma. It will also study how this treatment affects disease markers and immune system recovery to see if there's a link to patient outcomes.See study design
What are the potential side effects?
Daratumumab may cause infusion reactions like coughing or difficulty breathing; fatigue; nausea; fever; chills; bone pain. It can also affect blood counts leading to increased risk of infections or bleeding.

ALLO-T-DART Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My T-cell acute lymphoblastic leukemia is in remission or responded well after more treatment.
Select...
I can do most of my daily activities without help.
Select...
My organs are functioning well.
Select...
I am scheduled for a stem cell transplant with a donor already found.
Select...
I am between 0 and 39 years old.
Select...
I have no lingering side effects from previous cancer treatments.

ALLO-T-DART Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Patients with dose limiting toxicity (per CTCAE v.5)
Secondary outcome measures
Relapse free survival

Side effects data

From 2024 Phase 3 trial • 498 Patients • NCT02136134
60%
Thrombocytopenia
50%
Peripheral sensory neuropathy
47%
Peripheral Sensory Neuropathy
36%
Upper respiratory tract infection
36%
Diarrhoea
29%
Cough
28%
Anaemia
23%
Fatigue
23%
Upper Respiratory Tract Infection
23%
Constipation
21%
Back pain
20%
Arthralgia
20%
Oedema peripheral
19%
Neutropenia
19%
Dyspnoea
18%
Insomnia
17%
Pyrexia
16%
Oedema Peripheral
15%
Nausea
14%
Pain in extremity
14%
Lymphopenia
14%
Nasopharyngitis
14%
Bronchitis
14%
Neuralgia
13%
Back Pain
13%
Dizziness
12%
Decreased appetite
12%
Vomiting
12%
Headache
12%
Hypertension
11%
Conjunctivitis
11%
Asthenia
11%
Pneumonia
11%
Hypokalaemia
10%
Musculoskeletal chest pain
10%
Muscle spasms
9%
Urinary tract infection
9%
Bone pain
9%
Leukopenia
9%
Decreased Appetite
9%
Hyperglycaemia
9%
Pain in Extremity
9%
Bronchospasm
8%
Alanine aminotransferase increased
8%
Abdominal pain upper
8%
Weight decreased
8%
Muscle Spasms
7%
Hypophosphataemia
7%
Herpes zoster
7%
Influenza
7%
Hypocalcaemia
7%
Alanine Aminotransferase Increased
7%
Rash
6%
Musculoskeletal Chest Pain
6%
Aspartate aminotransferase increased
6%
Myalgia
6%
Abdominal pain
6%
Nasal congestion
5%
Bone Pain
5%
Hypotension
5%
Abdominal Pain Upper
5%
Weight Decreased
5%
Chills
5%
Productive cough
5%
Throat irritation
5%
Herpes Zoster
5%
Oedema
5%
Paraesthesia
5%
Epistaxis
4%
Dyspepsia
2%
Atrial fibrillation
2%
Acute kidney injury
2%
Sepsis
2%
Atrial Fibrillation
1%
Acute myocardial infarction
1%
Humerus fracture
1%
Pneumonia cytomegaloviral
1%
Rib fracture
1%
Lower Respiratory Tract Infection
1%
Squamous cell carcinoma of skin
1%
Pulmonary sepsis
1%
Febrile neutropenia
1%
Pleural effusion
1%
Acute coronary syndrome
1%
Pulmonary Sepsis
1%
Hypercalcaemia
1%
Pneumonia Cytomegaloviral
1%
Cardiac failure congestive
1%
Femur fracture
1%
Lower respiratory tract infection
1%
Hip fracture
1%
Angina unstable
1%
Cerebrovascular accident
1%
Ischaemic stroke
1%
Respiratory failure
1%
Bronchitis chronic
1%
Gastroenteritis
1%
Pathological fracture
1%
Ischaemic Stroke
1%
Respiratory Failure
1%
Pathological Fracture
1%
Febrile Neutropenia
1%
Cardiac Failure Congestive
1%
Bronchopneumonia
1%
Femur Fracture
1%
Humerus Fracture
1%
Acute Kidney Injury
1%
Pleural Effusion
100%
80%
60%
40%
20%
0%
Study treatment Arm
Daratumumab + Bortezomib and Dexamethasone (DVd)
Bortezomib + Dexamethasone (Vd)
Switch From Bortezomib + Dexamethasone (Vd) to Daratumumab Monotherapy

ALLO-T-DART Trial Design

1Treatment groups
Experimental Treatment
Group I: InterventionalExperimental Treatment1 Intervention
Phase 1: 3 dose levels to determine safety (15 patients) Dose expansion: Daratumumab (DARA) treatment post-HCT Induction: DARA IV weekly x 8 doses (Weeks 1-8) Consolidation: DARA IV every 2 weeks x 8 doses (Weeks 9-24) Maintenance: DARA IV every 4 weeks (Stop at Day +270)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Daratumumab
FDA approved

Find a Location

Who is running the clinical trial?

New York Medical CollegeLead Sponsor
69 Previous Clinical Trials
6,031 Total Patients Enrolled
Troy Quigg, DOStudy ChairHelen DeVos Children's Hospital
1 Previous Clinical Trials
95 Total Patients Enrolled
Allyson Flower, MDStudy ChairMemorial Sloan Kettering Cancer Center

Media Library

Interventional Clinical Trial Eligibility Overview. Trial Name: NCT04972942 — Phase 1
Acute Lymphoblastic Leukemia Research Study Groups: Interventional
Acute Lymphoblastic Leukemia Clinical Trial 2023: Interventional Highlights & Side Effects. Trial Name: NCT04972942 — Phase 1
Interventional 2023 Treatment Timeline for Medical Study. Trial Name: NCT04972942 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you elaborate on the most common applications for Daratumumab?

"Daratumumab is a biological response modifier, typically utilized to treat refractory multiple myeloma, relapsed or refractory multiple myeloma, and cell transplants."

Answered by AI

How many participants are enrolling in this clinical trial?

"Affirmative, clinicaltrials.gov's data verifies that this medical trial is actively searching for participants. The investigation was first posted on May 22nd 2023 and the latest update to the study occured June 29th 2023. 30 patients are needed at a single site for enrollment."

Answered by AI

Is there still an opportunity for individuals to participate in this research endeavor?

"Indeed, the clinicaltrials.gov repository attests to this trial's recruitment process being ongoing. Initially posted on 22nd May 2023 and last modified on 29th June 2023, it is seeking 30 participants at one medical facility."

Answered by AI

Has Daratumumab attained authorization from the FDA?

"Due to its Phase 1 classification, our team at Power has assigned a score of 1 out of 3 for Daratumumab's safety profile. This denotes there is limited data concerning the efficacy and security of this medication."

Answered by AI

Has Daratumumab been studied in any other research initiatives?

"Currently, 124 clinical trials are in progress for Daratumumab with 24 of those located at the third phase. The primary research hub is Basking Ridge, New jersey although there exist 5783 sites studying this medication across the nation."

Answered by AI
~20 spots leftby Sep 2027